Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32 – Business Wire (press release)
|
Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32
Business Wire (press release) Data presented by Dr. Brian Gastman of the Cleveland Clinic at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Md. showed that treatment with ALKS 4230 significantly delayed tumor growth and led to accumulation of … |
